Oral weight-loss drug VK2735 enters Phase 3 trials to evaluate efficacy over 68 weeks
Viking will evaluate the weight-loss effects of a once-daily oral dual GLP-1/GIP receptor agonist in a total of 1,120 adults. As development moves from short-term weight loss toward long-term treatment, sustained efficacy and patient tolerability will be central to these trials.